TSRL, Inc

TSRL, Inc. was awarded up to $3.6 million in grant funding from the National Institute of Allergy & Infectious Diseases to develop novel antibacterials for difficult-to-treat skin and soft tissue infections.

Therapeutic Systems Research Laboratories (TSRL), Inc., announced today that the company was awarded a Phase I SBIR grant from the National Institute of Allergy & Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).